# Closure of atrial septal defect and patent foramen ovale

Intervention · id `cardio:closure-of-pfo-and-asd` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: PFO closure; ASD closure; Septal closure

Browse, organ or system: Heart  
Browse, condition area: Stroke; Valve and congenital heart disease  

## In plain language

Closing an atrial septal defect or a patent foramen ovale means shutting the opening between the two upper chambers of the heart, with a catheter-delivered implant or by surgery. MeSH describes a septal occluder device as a catheter-delivered implant used for closing abnormal holes in the cardiovascular system, especially heart septal defects. A 2023 open-access review says transcatheter device closure is the preferred way of closing septum secundum defects and that careful patient selection and follow-up are necessary. A 2026 review says the indications, timing and long-term safety of patent foramen ovale closure remain controversial.

## Technical summary

MeSH descriptor D055989, Septal Occluder Device (broad, because the descriptor names the implant and not the procedure). Its scope note describes a catheter-delivered implant used for closing abnormal holes in the cardiovascular system, especially heart septal defects. MedlinePlus lists cardiac catheterization to repair simple defects, such as a small hole in the inside wall of the heart, among the treatments for congenital heart defects. A 2023 open-access narrative review of closure devices for atrial septal defect (Cureus, CC BY 3.0) says transcatheter device closure is the preferred way of closing septum secundum defects; that a meta-analysis found the transcatheter approach had a high success rate and lower rates of adverse events and shorter hospital stays than surgery; and that complications are relatively rare. A 2026 open-access review of patent foramen ovale (MedComm, CC BY 4.0) says transcatheter closure has evolved into a secondary prevention strategy for patients with a PFO-related stroke, that apart from three randomized trials in stroke secondary prevention no other randomized trial has yielded encouraging results, and that long-term surveillance for arrhythmias and residual shunts is still needed. These are the reviews' statements; the atlas gives no rule about who should have an opening closed, by which route, or what medicine follows, and records no trial figures. The US approval of one device for secundum atrial septal defect is on that product's own page.

## Claims, with the population each applies to

## Context: People having an atrial septal defect closed (2023 device review)

Recipient: Recipient not specified; Population: People whose atrial septal defect is closed through a catheter, as the review describes them. It also covers some patients with a patent foramen ovale, and the comparison with surgery.; Care setting: Catheterization laboratory, as the review describes the procedure. Surgery is mentioned only as a comparison.; Geography: The review discusses United States device approvals; this record does not use them.; Life stage: Not restricted in the abstract or introduction. The review includes studies of adults and of children; this record makes no statement about newborns, pregnancy or any age group.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (a narrative review; follow-up periods of individual studies are not recorded).

### A 2023 open-access narrative review of devices for transcatheter closure of atrial septal defect (Cureus) says transcatheter device closure is the preferred way of closing septum secundum defects. It says a meta-analysis found the transcatheter approach had a high success rate, lower rates of adverse events and shorter hospital stays compared with surgery, that complications have been reported but are relatively rare, and that careful patient selection and follow-up are necessary to minimize complications and ensure optimal outcomes. MedlinePlus lists cardiac catheterization to repair simple defects, such as a small hole in the inside wall of the heart, among the treatments for congenital heart defects.

- Category: Description
- Evidence stage: Evidence synthesis
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People whose atrial septal defect is closed through a catheter, as the review describes them. It also covers some patients with a patent foramen ovale, and the comparison with surgery.; Care setting: Catheterization laboratory, as the review describes the procedure. Surgery is mentioned only as a comparison.; Geography: The review discusses United States device approvals; this record does not use them.; Life stage: Not restricted in the abstract or introduction. The review includes studies of adults and of children; this record makes no statement about newborns, pregnancy or any age group.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (a narrative review; follow-up periods of individual studies are not recorded).
- Limitations: A narrative review of devices, written in 2023; the outcome statements come from studies it cites, and its device list and trial figures are not repeated. The review mentions surgical closure only in comparison. The atlas states no rule about who should have a defect closed or by which route; the MedlinePlus sentence is general patient information.
- Last checked: 2026-11-18
- Sources:
  1. Supports: Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329454/>
     Locator: Introduction and background, para 1, sentence 9 (first part). Retrieved 2026-11-18T17:25:50Z. Source state: Current. Version fingerprint: 53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64.
     How it applies: Transcatheter device closure is the preferred way to close septum secundum defects.
  2. Supports: Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329454/>
     Locator: Abstract, para 1, sentence 15 (first part). Retrieved 2026-11-18T17:25:50Z. Source state: Current. Version fingerprint: 53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64.
     How it applies: A meta-analysis found the transcatheter approach had a high success rate.
  3. Supports: Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329454/>
     Locator: Abstract, para 1, sentence 15 (end). Retrieved 2026-11-18T17:25:50Z. Source state: Current. Version fingerprint: 53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64.
     How it applies: Lower rates of adverse events and shorter hospital stays than surgery.
  4. Supports: Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329454/>
     Locator: Abstract, para 1, sentence 16 (first part). Retrieved 2026-11-18T17:25:50Z. Source state: Current. Version fingerprint: 53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64.
     How it applies: Complications of transcatheter closure have been reported.
  5. Supports: Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329454/>
     Locator: Abstract, para 1, sentence 17. Retrieved 2026-11-18T17:25:50Z. Source state: Current. Version fingerprint: 53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64.
     How it applies: Complications are relatively rare.
  6. Supports: Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Cureus 2023), fetched 2026-11-18. A narrative review. Used for what the review says about transcatheter closure of atrial septal defects; the device list and trial figures are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC10329454/>
     Locator: Abstract, para 1, sentence 20. Retrieved 2026-11-18T17:25:50Z. Source state: Current. Version fingerprint: 53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64.
     How it applies: Careful patient selection and follow-up are necessary.
  7. Supports: Congenital Heart Defects (MedlinePlus health topic) (Webpage, edition Page fetched 2026-10-14. The page shows a last-updated date in its footer; it is not used here.) <https://medlineplus.gov/congenitalheartdefects.html>
     Locator: Summary, What are the treatments for congenital heart defects?. Retrieved 2026-10-14T18:21:54Z. Source state: Current. Version fingerprint: 8a8235db9024c57a4d94c6eca43f79959079f4a59cadc7bbe15b9e7e583f480d.
     How it applies: MedlinePlus: cardiac catheterization to repair simple defects.
  8. Background: MeSH scope note for descriptor D055989 (Septal Occluder Device) (Dataset, edition MeSH linked-data record of the preferred concept M0524981 of descriptor D055989, fetched 2026-11-18. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0524981>
     Locator: scopeNote.@value, sentence 1 (first part). Retrieved 2026-11-18T17:23:30Z. Source state: Current. Version fingerprint: 0bf9f56e8a4655464b7574c149341ac7e89f41d00cf0fa2f804e89c01d274f37.
     How it applies: MeSH scope note for a septal occluder device.

## Context: People having a patent foramen ovale closed (2026 review)

Recipient: Recipient not specified; Population: People with a patent foramen ovale whose closure is considered, mainly after a PFO-related stroke, as the review describes them.; Care setting: Not stated for the review as a whole. The review discusses the closure procedure and its follow-up.; Geography: Not stated for the review as a whole.; Life stage: Not restricted. The review lists elderly people, children, pregnant women and athletes as groups in whom diagnostic and predictive tools need further investigation; this record makes no statement about them.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (a narrative review; follow-up periods of individual studies are not recorded).

### A 2026 open-access review of patent foramen ovale (MedComm) says transcatheter closure has evolved into a secondary prevention strategy for patients with a PFO-related stroke, and that substantial evidence has established transcatheter closure for secondary prevention in patients with cryptogenic stroke. It says the indications, timing and long-term safety of closure remain controversial, that long-term surveillance for complications such as arrhythmias and residual shunts is still needed, and that apart from three randomized trials in stroke secondary prevention no other randomized trial has yielded encouraging results for closure.

- Category: Description
- Evidence stage: Evidence synthesis
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People with a patent foramen ovale whose closure is considered, mainly after a PFO-related stroke, as the review describes them.; Care setting: Not stated for the review as a whole. The review discusses the closure procedure and its follow-up.; Geography: Not stated for the review as a whole.; Life stage: Not restricted. The review lists elderly people, children, pregnant women and athletes as groups in whom diagnostic and predictive tools need further investigation; this record makes no statement about them.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (a narrative review; follow-up periods of individual studies are not recorded).
- Limitations: A narrative review; the statements come from its abstract, introduction and conclusions, which cite the trials without giving figures here. The review uses the abbreviation CS for cryptogenic stroke. Trial figures, device types and patient-selection criteria are not repeated, and the atlas states no rule about who should have a patent foramen ovale closed.
- Last checked: 2026-11-18
- Sources:
  1. Supports: Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13547099/>
     Locator: Introduction, para 2, sentence 4 (part). Retrieved 2026-11-18T17:25:47Z. Source state: Current. Version fingerprint: f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096.
     How it applies: Transcatheter closure has evolved into a secondary prevention strategy for PFO-related stroke.
  2. Supports: Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13547099/>
     Locator: Conclusions and Perspectives, para 1, sentence 3. Retrieved 2026-11-18T17:25:47Z. Source state: Current. Version fingerprint: f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096.
     How it applies: Substantial evidence has established closure for secondary prevention in cryptogenic stroke.
  3. Supports: Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13547099/>
     Locator: Abstract, para 1, sentence 3 (end). Retrieved 2026-11-18T17:25:47Z. Source state: Current. Version fingerprint: f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096.
     How it applies: Indications, timing and long-term safety remain controversial.
  4. Supports: Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13547099/>
     Locator: Conclusions and Perspectives, para 2, sentence 4 (end). Retrieved 2026-11-18T17:25:47Z. Source state: Current. Version fingerprint: f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096.
     How it applies: Long-term surveillance for complications such as arrhythmias and residual shunts is still needed.
  5. Supports: Patent Foramen Ovale: Epidemiology, Risk Factors, Pathophysiology, Clinical Features, Diagnosis, and Management (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (MedComm 2026), fetched 2026-11-18. A narrative review. Used for how common a patent foramen ovale is, the conditions linked with it, and what the review says about closure; diagnostic detail and device types are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC13547099/>
     Locator: Conclusions and Perspectives, para 3, sentence 1. Retrieved 2026-11-18T17:25:47Z. Source state: Current. Version fingerprint: f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096.
     How it applies: Apart from three trials in stroke secondary prevention, no other randomized trial has yielded encouraging results.

## Connected pages

- A 2023 review says transcatheter device closure is the preferred way to close septum secundum defects; its outcome statements come from studies it cites: Atrial septal defect (`cardio:atrial-septal-defect`) [a claim, not a settled fact; see claim `cardio:claim-asd-device-closure-review` and its context]
- A 2026 review says closure is a secondary prevention strategy for PFO-related stroke, and that indications, timing and long-term safety remain controversial: Patent foramen ovale (`cardio:patent-foramen-ovale`) [a claim, not a settled fact; see claim `cardio:claim-pfo-closure-review` and its context]
- A closure device; its US approval covers secundum atrial septal defect closure through a catheter: Amplatzer Septal Occluder (`cardio:amplatzer-septal-occluder`)
- Filed under this front: Procedures and surgery (`cardio:front-procedures-and-surgery`)

## Provenance

Content hash: 0282e2149425c7be527744bb38787576a955e48f5c47edfc636b21264b6dd37e
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
